Literature DB >> 29512213

The role of the dermatologist in Raynaud's phenomenon: a clinical challenge.

C Matucci-Cerinic1, V Nagaraja2, F Prignano1, B Kahaleh3, S Bellando-Randone4,5.   

Abstract

Raynaud's phenomenon (RP) is a functional vascular disorder involving extremities. In his practice, the dermatologist may frequently encounter RP which affects mainly women and is categorized into a primary benign form and a secondary form associated with different diseases (infections, drugs, autoimmune and vascular conditions, haematologic, rheumatologic and endocrinologic disorders). Still today, the differential diagnosis is a clinical challenge. Therefore, a careful history and a physical examination, together with laboratory tests and nailfold capillaroscopy, is mandatory. RP is generally benign, but a scheduled follow-up for primary RP patients should be established, due to risk of evolution to secondary RP. A combination of conservative measures and medications can help in the management of RP. The importance of avoiding all potential physical, chemical and emotional triggers, as well as quitting smoking, should be strongly suggested to the patient. As first-line treatment, dihydropyridine calcium channel blockers should be used. If this approach is not sufficient, prostacyclin derivatives, phosphodiesterases inhibitors and endothelin receptor antagonists can be considered as second-line treatment. In cases of acute ischaemia, nifedipine and intravenous prostanoids are helpful. In refractory cases, botulinum injections have shown a significant benefit. The approach to the RP patients requires therefore a coordinated care of specialists together with the primary care physician.
© 2018 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2018        PMID: 29512213     DOI: 10.1111/jdv.14914

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  3 in total

1.  Perfusion Scintigraphy for the Evaluation of Patients with Raynaud's Phenomenon.

Authors:  Ari Chong
Journal:  Nucl Med Mol Imaging       Date:  2020-10-22

Review 2.  Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

Authors:  Ming Zhao; Jiali Wu; Haijing Wu; Amr H Sawalha; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-15       Impact factor: 8.667

Review 3.  Raynaud's Phenomenon with Focus on Systemic Sclerosis.

Authors:  Magdalena Maciejewska; Mariusz Sikora; Cezary Maciejewski; Rosanna Alda-Malicka; Joanna Czuwara; Lidia Rudnicka
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.